NCT05123599 - A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

July 31, 2023

Study Completion Date

June 26, 2024

Conditions

Hepatitis B, Chronic

Interventions

DRUG

JNJ-73763989

JNJ-73763989 injection will be administered subcutaneously.

BIOLOGICAL

JNJ-64300535

JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.

DRUG

ETV monohydrate

ETV monohydrate film-coated tablets will be administered orally.

DRUG

Tenofovir disoproxil

Tenofovir disoproxil film-coated tablets will be administered orally.

DRUG

TAF

TAF film-coated tablets will be administered orally.

Trial Locations (13)

333

Chang Gung Memorial Hospital Linkou Branch, Taoyuan District

1010

New Zealand Clinical Research, Auckland

2650

UZ Antwerpen, Edegem

UZA-SGS, Edegem

20122

Irccs Ospedale Maggiore Di Milano, Milan

39008

Hosp. Univ. Marques de Valdecilla, Santander

56124

Azienda Ospedaliero Universitaria Pisana, Pisa

69004

Hopital de La Croix Rousse, Lyon

82445

E-DA Hospital, Kaohsiung City

92110

Hopital Beaujon, Clichy

41-400

ID Clinic, Mysłowice

08035

Hosp Univ Vall D Hebron, Barcelona

SE5 9RF

Kings College Hospital, London

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY